Patients with post-IPI therapy N = 111 | |
Demographic characteristics measured at index | |
Age, mean (SD) | 57.1 (13.1) |
Male, % | 64.9 |
Medicare beneficiary, % | 26.1 |
Insurance plan type, % | |
Comprehensive | 5.4 |
EPO | 0.9 |
HMO | 4.5 |
POS (includes w/capitation) | 5.4 |
PPO | 67.6 |
Other (basic/major medical, CHDP, HDHP) | 9.9 |
Unknown/missing | 6.3 |
Clinical characteristics measured at index and during baseline period | |
Baseline National Cancer Institute comorbidity index, mean (SD) | 0.4 (0.8) |
Baseline unique number of National Drug Codes, mean (SD) | 11.9 (7.5) |
Baseline selected comorbid conditions with >5% prevalence, % |
|
Brain/leptomeningeal metastasis | 35.1 |
Hypertension | 33.3 |
Chronic liver disease | 14.4 |
Myocardial infarction/coronary artery disease | 11.7 |
Diabetes | 9.9 |
Cerebrovascular disease | 8.1 |
Renal disease | 7.2 |
Autoimmune disorders | 6.3 |
Congestive heart failure | 5.4 |
Ocular melanoma | 5.4 |
Diagnosing physician specialty, % |
|
Oncologist/hematologist | 26.1 |
General surgeon | 16.2 |
Dermatologist | 0.9 |
Primary care provider | 9.9 |
Radiologist/nuclear medicine | 17.1 |
Other specialist | 10.8 |
Other provider | 0.9 |
Facility | 9.9 |
Unknown | 8.1 |